deltatrials
Completed PHASE1 NCT00002721

Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

A PHASE I TRIAL OF ESTRAMUSTINE PHOSPHATE AND DOXORUBICIN IN HORMONE REFRACTORY METASTATIC PROSTATE CANCER

Sponsor: University of New Mexico

Conditions Prostate Cancer
Interventions doxorubicin hydrochloride drug resistance inhibition treatment estramustine phosphate sodium
Updated 5 times since 2017 Last updated: May 20, 2014 Started: Mar 31, 1995 Primary completion: Jun 30, 2013 Completion: Jun 30, 2013

This PHASE1 trial investigates Prostate Cancer and is currently completed. University of New Mexico leads this study, which shows 5 recorded versions since 1995 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Mar 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of New Mexico
Data source: University of New Mexico

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Albuquerque, United States